Novo Nordisk Shares Drop 12% After Alzheimer's Drug Trial Fails to Meet Main Goal
Novo Nordisk A/S announced the top-line results from the two-year primary analysis of the evoke and evoke+ phase 3 trials evaluating oral semaglutide in early-stage symptomatic Alzheimer's disease. The trials, which enrolled a total of 3,808 adults, did not demonstrate a statistically significant reduction in Alzheimer's disease progression compared to placebo, as measured by the Clinical Dementia Rating - Sum of Boxes score. While improvements in Alzheimer's disease-related biomarkers were observed, these did not translate into a delay in disease progression. The 1-year extension period for both trials will be discontinued based on these efficacy results. Topline results will be presented at the Clinical Trials in Alzheimer's Disease conference on December 3, 2025, with full results scheduled for presentation at the 2026 Alzheimer's and Parkinson's Diseases Conferences in March 2026.Disclaimer: This news brief was created by Public Technologies using generative artificial intellig